Clinical trialNCT06917911RecruitingPhase 2Interventional

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

SponsorNational Cancer Institute (NCI)Enrollment162Core Binding Factor Acute Myeloid Leukemia

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Celalettin Ustun
Alliance for Clinical Trials in Oncology
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Kootenai Health - Coeur D'Alene
Coeur d'Alene, Idaho, United States
John M. Schallenkamp
Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho, United States
John M. Schallenkamp
Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho, United States
John M. Schallenkamp
Recruiting
the James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky, United States
Mohamed M. Hegazi
Recruiting
Uofl Health Medical Center Northeast
Louisville, Kentucky, United States
Mohamed M. Hegazi
Recruiting
Trinity Health Iha Medical Group Hematology Oncology - Brighton
Brighton, Michigan, United States
Tareq Al baghdadi
Recruiting
Trinity Health Iha Medical Group Hematology Oncology - Canton
Canton, Michigan, United States
Tareq Al baghdadi
Recruiting
Trinity Health Iha Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan, United States
Tareq Al baghdadi
Recruiting
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, United States
Tareq Al baghdadi
Recruiting
Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac, Michigan, United States
Tareq Al baghdadi
Recruiting
Trinity Health Iha Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, Michigan, United States
Tareq Al baghdadi
Recruiting
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus, Mississippi, United States
Salil Goorha
Recruiting
Baptist Cancer Center-Grenada
Grenada, Mississippi, United States
Salil Goorha
Recruiting
Baptist Memorial Hospital and Cancer Center-Union County
New Albany, Mississippi, United States
Salil Goorha
Recruiting
Baptist Memorial Hospital and Cancer Center-Oxford
Oxford, Mississippi, United States
Salil Goorha
Recruiting
Baptist Memorial Hospital and Cancer Center-Desoto
Southhaven, Mississippi, United States
Salil Goorha
Recruiting
Bozeman Health Deaconess Hospital
Bozeman, Montana, United States
John M. Schallenkamp
Recruiting
Benefis Sletten Cancer Institute
Great Falls, Montana, United States
John M. Schallenkamp
Recruiting
Community Medical Center
Missoula, Montana, United States
John M. Schallenkamp
Recruiting
University of Rochester
Rochester, New York, United States
Bassil Botros
Recruiting
Baptist Memorial Hospital and Cancer Center-Collierville
Collierville, Tennessee, United States
Salil Goorha
Recruiting
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee, United States
Salil Goorha
Recruiting
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, United States
Michael O. Ojelabi
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 2 Feb 2027
Primary completion: 25 Nov 2027
Completion: 25 Nov 2027
Last update posted: 9 Jul 2026
Registered enrollment: 162
Registry id: NCT06917911

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.